This bibliography shows the most interesting papers selected from pmc PubMedCentral which were newly included in covid009I |
PMC7289108 1. Structural analysis of the putative SARS-CoV-2 primase complex. |
| *32535228* 32535228 | |
PMC7215129 2. Allo-priming as a universal anti-viral vaccine: protecting elderly from current COVID-19 and any future unknown viral outbreak. |
| *32398026* 32398026 | |
PMC7286221 3. COVID-19: viral-host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection. |
| *32522207* 32522207 | |
PMC7266426 4. The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic. |
| *32487093* 32487093 | |
PMC7113866 5. Rapid manipulation of the porcine epidemic diarrhea virus genome by CRISPR/Cas9 technology. |
| *31712093* 31712093 | |
PMC7213072 6. Summary of the coronavirus disease 2019 (COVID-19) update from the 2020 Conference on Retroviruses and Opportunistic Infections, 8-11 March 2020, Boston, USA. |
| *32405428* 32405428 | |
PMC7243161 7. Postmortem Examination of Patients With COVID-19. |
| *32437497* 32437497 | |
PMC7265655 8. A Snapshot of SARS-CoV-2 Genome Availability up to April 2020 and its Implications: Data Analysis. |
| *32412415* 32412415 | |
PMC7246017 9. The case of Complement activation in COVID-19 multiorgan impact. |
| *32461141* 32461141 | |
PMC7242192 10. Electron Microscopic Investigations in COVID-19: Not all Crowns Are Coronas. |
| *32446936* 32446936 | |
PMC7276225 11. Thrombotic microangiopathy in a patient with COVID-19. |
| *32525010* 32525010 | |
PMC7206432 12. Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. |
| *32437766* 32437766 | |
PMC7207116 13. Autophagy inhibition by chloroquine and hydroxychloroquine could adversely affect acute kidney injury and other organ injury in critically ill patients with COVID-19. |
| *32437765* 32437765 | |
PMC7230145 14. Kidney biopsy findings in a critically ill COVID-19 patient with dialysis-dependent acute kidney injury: a case against "SARS-CoV-2 nephropathy". |
| *32426558* 32426558 | |
PMC7237172 15. Electron microscopy of SARS-CoV-2: a challenging task. |
| *32442529* 32442529 | |
PMC7237177 16. Electron microscopy of SARS-CoV-2: a challenging task - Authors' reply. |
| *32442527* 32442527 | |
PMC7247793 17. COVID-19-associated hyperviscosity: a link between inflammation and thrombophilia? |
| *32464112* 32464112 | |
PMC7241971 18. Detection of SARS-CoV-2 in human breastmilk. |
| *32446324* 32446324 | |
PMC7205732 19. Research during SARS-CoV-2 pandemic: To "Preprint" or not to "Preprint", that is the question. |
| *32482418* 32482418 | |
PMC7211589 20. Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis. |
| *32395713* 32395713 | |
PMC7261103 21. What would Sergio Ferreira say to your physician in this war against COVID-19: How about kallikrein/kinin system? |
| *32504925* 32504925 | |
PMC7246007 22. Genetic variation in SARS-CoV-2 may explain variable severity of COVID-19. |
| *32464496* 32464496 | |
PMC7245229 23. COVID-19: Loss of bridging between innate and adaptive immunity? |
| *32505066* 32505066 | |
PMC7236693 24. "Therapeutic" facemasks. |
| *32460210* 32460210 | |
PMC7227545 25. Reflection on lower rates of COVID-19 in children: Does childhood immunizations offer unexpected protection? |
| *32425304* 32425304 | |
PMC7217120 26. COVID-19: beta-thalassemia subjects immunised? |
| *32447232* 32447232 | |
PMC7276137 27. Could the decrease in the endothelial nitric oxide (NO) production and NO bioavailability be the crucial cause of COVID-19 related deaths? |
| *32534341* 32534341 | |
PMC7276117 28. The intriguing commonality of NETosis between COVID-19 & Periodontal disease. |
| *32534340* 32534340 | |
PMC7274980 29. A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2? |
| *32534339* 32534339 | |
PMC7263251 30. Oral cancer and periodontal disease increase the risk of COVID 19? A mechanism mediated through furin and cathepsin overexpression. |
| *32505073* 32505073 | |
PMC7239020 31. COVID-19 as a cause of immune thrombocytopenia. |
| *32445664* 32445664 | |
PMC7199282 32. Digesting the crisis: autophagy and coronaviruses. |
| *32391393* 32391393 | |
PMC7217786 33. Comparative review of respiratory diseases caused by coronaviruses and influenza A viruses during epidemic season. |
| *32405236* 32405236 | |
PMC7241347 34. Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19. |
| *32446902* 32446902 | |
PMC7229726 35. Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency. |
| *32425647* 32425647 | |
PMC7206495 36. Near-Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Causing a COVID-19 Case in Peru. |
| *32381617* 32381617 | |
PMC7256271 37. Coding-Complete Genome Sequences of Two SARS-CoV-2 Isolates from Egypt. |
| *32467284* 32467284 | |
PMC7256270 38. Complete Genome Sequence of SARS-CoV-2 in a Tiger from a U.S. Zoological Collection. |
| *32467283* 32467283 | |
PMC7225546 39. Complete Genome Sequences of SARS-CoV-2 Strains Detected in Malaysia. |
| *32409547* 32409547 | |
40. Complete Genome Sequence of a Novel Coronavirus (SARS-CoV-2) Isolate from Bangladesh. |
| *32527780* 32527780 | |
PMC7252045 41. A rapid screening method for testing the efficiency of masks in breaking down aerosols. |
| *32501301* 32501301 | |
PMC7280818 42. Importance of the evaluation of systemic microvascular flow and reactivity in critically ill patients with coronavirus disease 2019 - COVID-19. |
| *32531352* 32531352 | |
PMC7211983 43. Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey. |
| *32393381* 32393381 | |
PMC7254017 44. Cadaverless anatomy: Darkness in the times of pandemic Covid-19. |
| *32518047* 32518047 | |
PMC7235550 45. Organoids demonstrate gut infection by SARS-CoV-2. |
| *32427981* 32427981 | |
PMC7252419 46. The non-specific and sex-differential effects of vaccines. |
| *32461674* 32461674 | |
PMC7251555 47. Kawasaki disease linked to COVID-19 in children. |
| *32461672* 32461672 | |
PMC7251553 48. Innate T cells in COVID-19: friend or foe? |
| *32461671* 32461671 | |
PMC7249038 49. Dysregulation of type I interferon responses in COVID-19. |
| *32457522* 32457522 | |
PMC7240244 50. COVID-19: the vasculature unleashed. |
| *32439870* 32439870 | |
PMC7224124 51. SARS-CoV-2 likes it cool. |
| *32409742* 32409742 | |
PMC7224130 52. Modulation of immune crosstalk in COVID-19. |
| *32409741* 32409741 | |
PMC7278217 53. Dissecting antibody-mediated protection against SARS-CoV-2. |
| *32514035* 32514035 | |
PMC7274045 54. SARS-CoV-2 cross-reactivity in healthy donors. |
| *32504061* 32504061 | |
PMC7273379 55. Immune evasion via SARS-CoV-2 ORF8 protein? |
| *32504060* 32504060 | |
PMC7273380 56. Many paths to COVID-19 lymphocyte dysfunction. |
| *32504059* 32504059 | |
PMC7264968 57. Blood clots and TAM receptor signalling in COVID-19 pathogenesis. |
| *32488201* 32488201 | |
PMC7291937 58. A versatile mouse model of COVID-19. |
| *32533111* 32533111 | |
PMC7291939 59. SARS-CoV-2 has a sweet tooth. |
| *32533110* 32533110 | |
PMC7288618 60. Considering how biological sex impacts immune responses and COVID-19 outcomes. |
| *32528136* 32528136 | |
PMC7225630 61. A spike with which to beat COVID-19? |
| *32415242* 32415242 | |
PMC7264971 62. Antimicrobial use, drug-resistant infections and COVID-19. |
| *32488173* 32488173 | |
PMC7289071 63. Bat-borne virus diversity, spillover and emergence. |
| *32528128* 32528128 | |
PMC7262486 64. COVID-19: organoids go viral. |
| *32483314* 32483314 | |
PMC7243953 65. Global Consortium Study of Neurological Dysfunction in COVID-19 (GCS-NeuroCOVID): Study Design and Rationale. |
| *32445105* 32445105 | |
PMC7238997 66. Severe acute respiratory syndrome coronavirus 2: virus mutations in specific European populations. |
| *32509310* 32509310 | |
PMC7234940 67. The role of selectivity of the SARS-CoV-2 virus for human genetic profiles in susceptibility and resistance to COVID-19. |
| *32483490* 32483490 | |
PMC7129032 68. Mutated COVID-19, May Foretells Mankind in a Great Risk in the Future. |
| *32292587* 32292587 | |
PMC7229440 69. Rare and extreme events: the case of COVID-19 pandemic. |
| *32427206* 32427206 | |
PMC7233254 70. Systemic endothelial dysfunction: a common pathway for COVID-19, cardiovascular and metabolic diseases. |
| *32425360* 32425360 | |
PMC7239175 71. Physician deaths from corona virus (COVID-19) disease. |
| *32409839* 32409839 | |
PMC7298678 72. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase. |
| *32532805* 32532805 | |
PMC7282200 73. Okulare Post-mortem-Befunde bei an COVID-19 verstorbenen Patienten. |
| *32519118* 32519118 | |
PMC7221376 74. The Myriad Ways in Which COVID-19 Revealed Character. |
| *32412525* 32412525 | |
PMC7282421 75. Detection and Isolation of SARS-CoV-2 in Serum, Urine, and Stool Specimens of COVID-19 Patients from the Republic of Korea. |
| *32528816* 32528816 | |
PMC7282418 76. Genome-Wide Identification and Characterization of Point Mutations in the SARS-CoV-2 Genome. |
| *32528815* 32528815 | |
PMC7281378 77. A Systematic Review Analyzing the Prevalence and Circulation of Influenza Viruses in Swine Population Worldwide. |
| *32397138* 32397138 | |
PMC7289638 78. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital. |
| *32529358* 32529358 | |
PMC7246029 79. Insights on early mutational events in SARS-CoV-2 virus reveal founder effects across geographical regions. |
| *32509472* 32509472 | |
PMC7247462 80. COVID-19 and Kawasaki disease in children. |
| *32464327* 32464327 | |
PMC7245191 81. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. |
| *32447571* 32447571 | |
PMC7267140 82. Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data. |
| *32462744* 32462744 | |
PMC7218701 83. A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19? |
| *32405877* 32405877 | |
PMC7236731 84. COVID-19 and asthma: To have or not to have T2 inflammation makes a difference? |
| *32466999* 32466999 | |
PMC7294821 85. Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case Series. |
| *32515676* 32515676 | |
PMC7215148 86. The potential role of TNFalpha in 2019 novel coronavirus pneumonia. |
| *32399393* 32399393 | |
PMC7227450 87. Cyclosporine therapy in cytokine storm due to coronavirus disease 2019 (COVID-19). |
| *32415310* 32415310 | |
PMC7290150 88. Targeting the immunology of coronavirus disease-19: synchronization creates symphony. |
| *32533292* 32533292 | |
PMC7267129 89. SARS-CoV-2 infection-induced immune responses: Friends or foes? |
| *32445403* 32445403 | |
PMC7243369 90. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. |
| *32434946* 32434946 | |
PMC7286545 91. Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California. |
| *32513865* 32513865 | |
PMC7210460 92. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro). |
| *32388537* 32388537 | |
PMC7239689 93. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2. |
| *32435059* 32435059 | |
PMC7289711 94. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. |
| *32532959* 32532959 | |
PMC7217340 95. Is COVID-19 a New Hematologic Disease? |
| *32399806* 32399806 | |
PMC7272136 96. Induced Pluripotent Stem Cells (iPSCs) Derived 3D Human Lung Organoids from Different Ethnicities to Understand the SARS-CoV2 Severity/Infectivity Percentage. |
| *32500482* 32500482 | |
PMC7282429 97. COVID-19 and lessons learned from the pandemic wave of meningococcal meningitis (1985-1990). |
| *32528206* 32528206 | |
PMC7282427 98. The Sudanese/British doctors who offered their lives fighting coronavirus (COVID-19) pandemic. |
| *32528193* 32528193 | |
PMC7245313 99. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. |
| *32505009* 32505009 | |
PMC7252011 100. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients? |
| *32387238* 32387238 | |
PMC7253999 101. Efficacy of face mask in preventing respiratory virus transmission: A systematic review and meta-analysis. |
| *32473312* 32473312 | |
PMC7151267 102. Ger Rijkers: Persistence of Memory in Times of COVID-19. |
| *32317245* 32317245 | |
PMC7211701 103. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. |
| *32423553* 32423553 | |
PMC7271831 104. SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts. |
| *32500504* 32500504 | |
PMC7250318 105. Mice with humanized-lungs and immune system - an idealized model for COVID-19 and other respiratory illness. |
| *32434416* 32434416 | |
PMC7223271 106. Multivariate analyses of codon usage of SARS-CoV-2 and other betacoronaviruses. |
| *32431949* 32431949 | |
PMC7282740 107. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein. |
| *32531235* 32531235 | |
PMC7217790 108. Gut microbiota and Covid-19- possible link and implications. |
| *32430279* 32430279 | |
PMC7228740 109. COVID-19: CADD to the rescue. |
| *32417181* 32417181 | |
PMC7228703 110. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2. |
| *32416259* 32416259 | |
111. Propagation, Inactivation, and Safety Testing of SARS-CoV-2. |
| *32517266* 32517266 | |
112. The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities. |
| *32512929* 32512929 | |
PMC7220177 113. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. |
| *32410760* 32410760 | |
PMC7220168 114. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. |
| *32410759* 32410759 | |
PMC7289569 115. Have deaths from COVID-19 in Europe plateaued due to herd immunity? |
| *32534627* 32534627 | |
PMC7289564 116. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. |
| *32534626* 32534626 | |
PMC7225404 117. SARS-CoV-2 in wastewater: potential health risk, but also data source. |
| *32246939* 32246939 | |
PMC7159059 118. Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility. |
| *32220289* 32220289 | |
PMC7252095 119. Prevention of the cytokine storm in COVID-19. |
| *32386610* 32386610 | |
PMC7279758 120. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. |
| *32526193* 32526193 | |
PMC7279719 121. Pathologists in pursuit of the COVID-19 culprit. |
| *32526191* 32526191 | |
PMC7250559 122. COVID-19 international neurological registries. |
| *32470417* 32470417 | |
PMC7252187 123. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. |
| *32386571* 32386571 | |
PMC7252006 124. Assessment of SARS-CoV-2 replication in the context of other respiratory viruses. |
| *32386570* 32386570 | |
PMC7255143 125. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. |
| *32473124* 32473124 | |
PMC7255254 126. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. |
| *32473123* 32473123 | |
PMC7241998 127. Organoids of human airways to study infectivity and cytopathy of SARS-CoV-2. |
| *32446313* 32446313 | |
PMC7228727 128. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. |
| *32422178* 32422178 | |
PMC7228737 129. Pulmonary fibrosis secondary to COVID-19: a call to arms? |
| *32422177* 32422177 | |
PMC7228732 130. Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. |
| *32427161* 32427161 | |
PMC7262681 131. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells. |
| *32483300* 32483300 | |
PMC7266583 132. The immune system and COVID-19: Friend or foe? |
| *32502542* 32502542 | |
PMC7246101 133. Could severe COVID-19 be considered a complementopathy? |
| *32430402* 32430402 | |
PMC7136682 134. We have to write and share valid and reliable information on COVID-19. |
| *32284797* 32284797 | |